Table 1 Demographic, clinical, genetic, and biomarker data of the entire group
Characteristic | No. (%) with available data | Mean (SD)/no. (%) |
|---|---|---|
Age at follow-up, years | 408 (100) | 61.2 (4.7) |
Female sex | 408 (100) | 246 (60.3) |
Education, years | 408 (100) | 13.5 (3.6) |
APOE-ɛ4 non-carriers | 408 (100) | 182 (44.6) |
APOE-ɛ4 heterozygous | 190 (46.6) | |
APOE-ɛ4 homozygous | 36 (8.8) | |
Negative AD family history (%) | 408 (100) | 21 (5.1) |
Positive AD family history, onset ≥ 75 years (%) | 124 (30.4) | |
Positive AD family history, onset < 75 years (%) | 263 (64.5 | |
CSF Aβ42/40 ratio | 387 (95) | 0.075 (0.02) |
CSF pTau, pg/mL | 387 (95) | 16.2 (7.6) |
CSF tTau, pg/mL | 387 (95) | 197.3 (73.3) |
CSF NfL, pg/mL | 387 (95) | 82.7 (30.5) |
CSF neurogranin, pg/mL | 387 (95) | 798.7 (331.6) |
FTM-PET uptake, centiloids | 352 (86) | 2.9 (17.0) |
FTM-PET positive visual reads | 350 (86) | 45 (12.9) |
PACC-like change/year | 406 (99.5) | 0.108 (0.5) |
BMI at baseline, Kg/m2 | 408 (100) | 26.8 (4.0) |
% weight change/year | 408 (100) | 0.049 (1.5) |
Systolic blood pressure, mmHg | 406 (99.5) | 127.3 (14.3) |
Total cholesterol, mg/dL | 408 (100) | 203.5 (30.5) |
Triglycerides, mg/dL | 408 (100) | 99.4 (58.8) |
HbA1c, % | 402 (98.5) | 5.5 (0.4) |
HADS total score | 407 (99.8) | 7.0 (5.1) |
Physical exercise, MET per week | 408 (100) | 3768.0 (2806.8) |
MEDAS score | 395 (96.8) | 9.3 (2.0) |